NCT06530810
Study of HS-10382 Combination in Patients With Chronic Myeloid Leukemia (CML) treatment 1 not_yet_recruiting NCT02348957
Treating Patients With Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) With Dasatinib No drug interventions Not Available Not Available completed NCT00510926
Exploratory Study of IMATINIB High Dose in Intermediate Risk Chronic Myeloid Leukemia in Chronic Phase treatment 2 completed NCT00123474
Chronic Myelogenous Leukemia (CML) - Follow on: Study of BMS-354825 in Subjects With CML treatment 3 completed NCT00324077
Phase I Study of Dasatinib (BMS-354825) and Imatinib in Subjects With Chronic Myeloid Leukemia in Chronic Phase treatment 1 withdrawn NCT00114959
Homoharringtonine With Oral Gleevec in Chronic, Accelerated and Blast Phase Chronic Myeloid Leukemia (CML) treatment 2 terminated NCT01872442
Combination of Dasatinib and Peg-Interferon Alpha 2b in First Line for Chronic Myeloid Leukemia in Chronic Phase Not Available 2 completed NCT01488253
Sirolimus/Tacrolimus Combination After HLA Matched Related Peripheral Blood Stem Cell Transplants prevention 2 terminated NCT03239886
Imatinib Discontinuation in Patients With Chronic Myeloid Leukemia Chronic Phase With Sustained MR4log No drug interventions treatment Not Available unknown_status NCT01650467
Imatinib Response in Patients With Chronic Myeloid Leukemia (CML) in Function of Abl Polymorphisms No drug interventions Not Available Not Available withdrawn NCT02888964
Pioglityazone and Imatinib for CML Patients treatment 2 completed NCT03807479
Study in Patients With Chronic Leukemia treatment 2 terminated NCT01856283
Nilotinib 300 mg BID in Newly Diagnosed CP-CML Patients to Verify Disappearance of CD34+/Lin-Ph+ Cells treatment 2 completed NCT00124748
Efficacy of 400 Mg Versus 800 Mg Imatinib in Chronic Myeloid Leukemia in Chronic Phase Patients - TOPS (Tyrosine Kinase Inhibitor Optimization and Selectivity) treatment 3 terminated NCT02767063
Therapies in Combination or Sequentially With Tyrosine Kinase Inhibitors (TKIs) in Chronic Phase Chronic Myelogenous Leukemia Patients in CCR (ACTIW) treatment 1 / 2 unknown_status NCT01827930
Phase III Trial Evaluating the Effectiveness of a Dose Adjustment of Imatinib Mesylate on the Molecular Response treatment 3 terminated NCT00103701
BMS-354825 in Patients With Chronic Accelerated, or Blast Phase Chronic Myelogenous Leukemia or Philadelphia Positive Acute Lymphoblastic Leukemia treatment 1 completed NCT01725204
Safety and Efficacy of Pegylated IFN-alpha 2B Added to Dasatinib in Newly Diagnosed Chronic Phase Myeloid Leukemia treatment 2 completed NCT00048672
Therapy of Early Chronic Phase CML With Gleevec treatment 2 completed NCT03509896
Study of Chinese Newly Diagnosed Participants With Philadelphia Chromosome-Positive (Ph+) Chronic Myeloid Leukemia in Chronic Phase (CML-CP) No drug interventions Not Available Not Available completed NCT04933526
The Efficacy and Safety of Switching to Flumatinib Versus Dasatinib After Imatinib-related Low-grade Adverse Events in CML-CP Patients treatment 4 unknown_status NCT04360005
Managed Access Programs for ABL001, Asciminib Not Available Not Available available NCT00451035
Efficacy and Safety of LBH589 in Adult Patients With Refractory Chronic Myeloid Leukemia (CML) in Chronic Phase treatment 2 terminated NCT03131986
Cessation of Tyrosine Kinase Inhibitors in Patients With Chronic-phase Chronic Myelogenous Leukaemia No drug interventions Not Available Not Available unknown_status NCT02782403
Axitinib and Bosutinib in Treating Patients With Chronic, Accelerated, or Blastic Phase Chronic Myeloid Leukemia treatment 1 terminated NCT00489203
Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer supportive_care 2 completed NCT01233921
Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer supportive_care Not Available completed NCT04258943
Bosutinib in Pediatric Patients With Newly Diagnosed Chronic Phase or Resistant/Intolerant Ph + Chronic Myeloid Leukemia treatment 1 / 2 active_not_recruiting NCT00890747
Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy treatment 1 completed NCT04605211
A Distress Reduction Intervention for Patients With BCR-ABL-Negative MPNs or CML on Tyrosine Kinase Inhibitors No drug interventions supportive_care Not Available completed NCT01177371
High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma treatment 2 completed NCT01558778
Mechanical Stimulation in Preventing Bone Density Loss in Patients Undergoing Donor Stem Cell Transplant No drug interventions supportive_care Not Available withdrawn NCT00101088
Temsirolimus and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia treatment 1 terminated NCT03647215
CALLS: CML and Ph+ALL Low Level Mutation Prevalence Survey No drug interventions Not Available Not Available completed NCT00025415
Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction treatment 1 completed NCT00118352
Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer treatment 2 completed NCT03907670
Chronic Myloid Leukemic Patients Treated With Tyrosine Kinase Inhibitor No drug interventions Not Available Not Available unknown_status NCT00723099
Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer treatment 2 completed NCT00005799
Fludarabine Phosphate, Low-Dose Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer treatment Not Available completed NCT00004918
Vaccine Therapy Plus Immune Adjuvant in Treating Patients With Chronic Myeloid Leukemia, Acute Myeloid Leukemia, or Myelodysplastic Syndrome treatment 1 / 2 completed NCT04838041
Protocol Number: HJKC3-0003. Treatment Free Remission After Combination Therapy With Asciminib (ABL001) Plus Tyrosine Kinase Inhibitors (TKI) in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation treatment 2 recruiting NCT01426334
Dasatinib and Cyclosporine in Treating Patients With Chronic Myelogenous Leukemia Refractory or Intolerant to Imatinib Mesylate treatment 1 terminated NCT01839916
Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies treatment 2 completed NCT00078858
Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant treatment 1 / 2 completed NCT01093586
Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies treatment 2 completed NCT05007873
ASTX727 and Dasatinib for the Treatment of Newly Diagnosed Philadelphia Chromosome or BCR-ABL Positive Chronic Myeloid Leukemia in Chronic Phase treatment 2 recruiting NCT01529827
Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies treatment 2 completed NCT06229860
Impact of Personality on Adherence to Tyrosine Kinase Inhibitor Therapy in Pts w/Chronic Myeloid Leukemia No drug interventions Not Available Not Available recruiting NCT00003694
Homoharringtonine Plus Low-Dose Cytarabine in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia in Chronic Phase treatment 2 completed NCT00030394
Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia treatment 2 completed NCT01199562
Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant Not Available Not Available completed NCT00049192
Oblimersen and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia treatment 2 completed NCT01159067
Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload supportive_care 2 terminated NCT00040846
Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies treatment 2 completed NCT00408681
Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell Transplant supportive_care Not Available completed NCT00450450
Donor Bone Marrow Transplant With or Without G-CSF in Treating Young Patients With Hematologic Cancer or Other Diseases treatment 3 completed NCT00702403
Nilotinib and Imatinib Mesylate After Donor Stem Cell Transplant in Treating Patients With ALL or CML treatment 1 / 2 completed NCT00006364
Homoharringtonine in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia treatment 2 completed NCT00343798
A Pilot Study to Evaluate the Co-Infusion of Ex Vivo Expanded Cord Blood Cells With an Unmanipulated Cord Blood Unit in Patients Undergoing Cord Blood Transplant for Hematologic Malignancies treatment 1 completed NCT00799461
Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications No drug interventions supportive_care 3 completed NCT00089011
Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer treatment 2 completed NCT00112593
Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer treatment Not Available completed NCT00856388
Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure Disorders treatment Not Available completed NCT00309907
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant treatment 2 completed NCT01175785
Infusion of Off-the-Shelf Expanded Cord Blood Cells to Augment Cord Blood Transplant in Patients With Hematologic Malignancies treatment 2 completed NCT01588015
Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant No drug interventions supportive_care 1 completed NCT01076270
Plerixafor and Filgrastim For Mobilization of Donor Peripheral Blood Stem Cells Before A Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies treatment Not Available terminated NCT01231919
MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia No drug interventions treatment 1 completed NCT00387426
Sunitinib in Treating Patients With Idiopathic Myelofibrosis treatment 2 terminated NCT04694820
A Mobile Intervention (txt4TKI) for the Improvement of Tyrosine Kinase Inhibitor Management in Patients With Chronic Myeloid Leukemia No drug interventions supportive_care Not Available completed NCT00012376
Chemotherapy Plus Sargramostim in Treating Patients With Refractory Myeloid Cancer treatment 1 completed NCT01053494
Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Cancer No drug interventions supportive_care Not Available completed NCT00795769
Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant supportive_care 2 completed NCT01427881
Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies treatment 2 completed NCT01056614
Fludarabine Phosphate, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Peripheral Blood Stem Cell Transplant, Tacrolimus, and Methotrexate in Treating Patients With Myeloid Malignancies treatment 2 completed NCT01789255
Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies supportive_care 2 completed NCT03883087
A Pivotal Study of HQP1351 in Patients of Chronic Myeloid Leukemia in Chronic Phase With T315I Mutation treatment 2 active_not_recruiting NCT04147533
Efficacy and Safety of TKIs' Withdrawal After a Two-step Dose Reduction in Patients With Chronic Myeloid Leukemia other 2 active_not_recruiting NCT04006847
Omega -3 Fatty Acid in Combination With Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia treatment 1 / 2 terminated NCT03332511
Efficacy and Safety of Nilotinib in CML-CP treatment 4 completed NCT06409936
PEARL Study: PotEntial of Asciminib in the eaRly Treatment of CML treatment 2 not_yet_recruiting NCT03459534
A Phase 3 Study for the Efficacy and Safety of Radotinib in CP-CML Patients With Failure or Intolerance to Previous TKIs treatment 3 recruiting NCT05638763
Cytochrome P450 Inhibition to Decrease Dosage of Dasatinib for Chronic Myelogenous Leukemia treatment 2 recruiting NCT04677439
Flumatinib in CML-CP Patients With Ph+ Post Imatinib Failure treatment 4 unknown_status NCT03885830
Precision Dosing of Tyrosine Kinase Inhibitors in CML Patients Not Available Not Available completed NCT03722420
Randomized Evaluation of Radotinib Versus Imatinib in Phase III Study for Efficacy With Chinese Patients (RERISE China) treatment 3 active_not_recruiting NCT03942094
Nilotinib for First-line Newly Diagnosed CML-CP Patients treatment 3 unknown_status NCT06119269
Ponatinib in CML Patients in Chronic Phase No drug interventions Not Available Not Available recruiting NCT02977312
Study of Cemivil® (Imatinib) in Chronic Myeloid Leukemia Patients in Jordan Not Available Not Available completed NCT03882281
Pharmacokinetics Profiles of HQP1351 Under Fasting and High-fat Meals in Patients With Chronic Myeloid Leukemia treatment 1 completed NCT06368414
A Study of Treatment-free Remission in Chronic Phase Chronic Myeloid Leukemia treatment 2 not_yet_recruiting NCT05311943
Treatment With Olverembatinib in CML-CP Patients Who Failed to at Least Two Previously Administered Second-generation TKIs. treatment 3 recruiting NCT06233890
The Analysis of Fatigue on Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukaemia No drug interventions Not Available Not Available active_not_recruiting NCT05543161
"Peripheral Blood Dipeptidylpeptidase IV (CD26) Positive Leukemic Stem Cells in Chronic Myeloid Leukemia as a Diagnostic Marker" No drug interventions Not Available Not Available unknown_status NCT03610971
Treatment Free Remission After Combination Therapy with Ruxolitinib Plus Tyrosine Kinase Inhibitors treatment 2 recruiting NCT03933852
Observational Study on Chronic Myeloid Leukemia Patients in Any Phase Treated With Ponatinib (Iclusig®) at Any Dose No drug interventions Not Available Not Available active_not_recruiting NCT06163430
CARDINAL- A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia No drug interventions treatment 1 not_yet_recruiting NCT06516029
Real-World Evaluation of Patient Characteristics and Treatment Patterns Among Patients With CML-CP Treated With Asciminib No drug interventions Not Available Not Available completed NCT05143840
Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase treatment 2 recruiting NCT04160546
Study to Evaluate the Reinduction and Second Stop of TKI With Ponatinib in CML in Molecular Response (ResToP) treatment 2 active_not_recruiting NCT04126681
A Pivotal Study of HQP1351 in Patients With Chronic Myeloid Leukemia in Chronic Phase treatment 2 active_not_recruiting NCT04793399
Safety and Efficacy Evaluation of Bosutinib Plus Atezolizumab in Newly Diagnosed Chronic Leukemia Adult Patients treatment 1 / 2 terminated NCT01593254
Study of Dasatinib vs Imatinib in Patients With Chronic Myeloid Leukemia (CML) Who Did Not Have Favorable Response to Imatinib treatment 2 completed NCT01933906
Addition of P1101 to Imatinib Treatment in Patients With Chronic Phase Chronic Myeloid Leukaemia Not Achieving a Complete Molecular Response treatment 1 completed NCT03045120
Determining Change in Cardiovascular and Metabolic Risks in Patients With Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States No drug interventions Not Available Not Available completed NCT01702064
Ruxolitinib in Combination With Nilotinib in Chronic Myeloid Leukemia (CML) Patients treatment 1 completed NCT01914484
Phase I/II Study of Nilotinib/Ruxolitinb Therapy for TKI Resistant Ph-Leukemia treatment 1 / 2 completed NCT02627677
A Study Comparing Ponatinib and Nilotinib in Participants With Chronic Myeloid Leukemia treatment 3 terminated NCT01660906
Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to Imatinib treatment 4 completed NCT01850004
Open-Label Study Evaluating Dasatinib Therapy Discontinuation in Patients With Chronic Phase Chronic Myeloid Leukemia With Stable Complete Molecular Response other 2 completed NCT03934372
Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors treatment 1 / 2 recruiting NCT01887561
Dasatinib for Patients Achieving Complete Molecular Response for Cure D-NewS Trial treatment 2 unknown_status NCT01464411
Dasatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia in Japan No drug interventions Not Available Not Available unknown_status NCT00038649
Therapy of Early Chronic Phase CML With Higher-Dose Gleevec, Alpha Interferon, and Low-Dose Ara-C treatment 2 terminated NCT05384587
Asciminib Monotherapy, With Dose Escalation, for 2nd and 1st Line Chronic Myelogenous Leukemia treatment 2 recruiting NCT00644878
Study of Molecular Response in Adult Patients on Nilotinib With Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (Ph+ CML) in Chronic Phase and a Suboptimal Molecular Response to Imatinib treatment 2 terminated NCT04666259
Asciminib in Monotherapy for Chronic Myeloid Leukemia in Chronic Phase (CML-CP) With and Without T315I Mutation treatment 3 completed NCT03842696
Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation prevention 1 / 2 recruiting NCT05794880
MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing No drug interventions treatment Not Available recruiting NCT06082804
Evaluation of Advanced Practice Nurse's Management of Patients With Chronic Myeloid Leukemia No drug interventions supportive_care Not Available recruiting NCT04925141
A Study of Dasatinib as First-line Treatment for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia (CML-CP) treatment 4 completed NCT03079505
Dasatinib Versus Nilotinib for Treatment Naïve Chronic Myeloid Leukemia treatment 3 terminated NCT01460693
Comparison of Imatinib Versus Dasatinib in Patients With Newly-diagnosed Chronic Phase Chronic Myeloid Leukaemia treatment 3 completed NCT02467270
Ponatinib in Participants With Resistant Chronic Phase Chronic Myeloid Leukemia (CP-CML) to Characterize the Efficacy and Safety of a Range of Doses treatment 2 active_not_recruiting NCT01761695
Chronic Myelod Leukemia Registry at Asan Medical Center No drug interventions Not Available Not Available terminated NCT01188278
Treatment With Second Generation Tyrosine Kinase Inhibitors (2G TKI) Post Imatinib Failure Survey Not Available Not Available completed NCT01061177
Nilotinib in Newly Diagnosed Adult Philadelphia Chromosome & /or BCR-ABL Positive Chronic Myeloid Leukaemia in Chronic Phase treatment 4 completed NCT05353205
A Study of the Efficacy and Safety of Flumatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase. treatment 4 recruiting NCT04883125
Value of Using Pioglitazone in Chronic Myeloid Leukemia Treatment treatment 2 completed NCT05367765
A Real World Study of the Efficacy and Safety of Flumatinib Versus Imatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase treatment 4 not_yet_recruiting NCT06423911
Study of Olverembatinib (HQP1351) in Patients With CP-CML treatment 3 recruiting NCT05367700
A Study of HS-10382 in Patients With Chronic Myeloid Leukemia. No drug interventions treatment 1 recruiting NCT02949570
Study to Assess Efficacy and Safety of Inecalcitol in Imatinib-Treated Residual Chronic Myeloid Leukaemia: INIM Study treatment 2 unknown_status NCT06121765
Metabolic Alternation and Clinicohematological Characteristic in Chronic Phase CML in Patient Treated With TKI No drug interventions Not Available Not Available not_yet_recruiting NCT01490775
Pilot Study to Assess Telemonitoring of Gleevec (Imatinib Mesylate) or Tasigna (Niltinib) Therapy No drug interventions supportive_care Not Available terminated